For research use only. Not for therapeutic Use.
ZL0580（Cat No.:I017134）is a high-purity small-molecule inhibitor of latent HIV-1 reactivation, making it a valuable tool in HIV latency and eradication research. By targeting key molecular pathways, ZL0580 suppresses HIV-1 transcription without activating latent reservoirs, offering insights into strategies for functional HIV cures. Its specificity and efficacy make it ideal for studying mechanisms underlying HIV latency and exploring therapeutic approaches to achieve sustained viral remission. ZL0580 is instrumental in advancing research on HIV persistence and the development of innovative antiretroviral therapies.
| Catalog Number | I017134 |
| CAS Number | 2377151-10-3 |
| Molecular Formula | C₂₅H₂₃F₃N₄O₄S |
| Purity | ≥95% |
| Target | Epigenetics |
| IUPAC Name | (2S)-N-phenyl-1-[4-[[4-(trifluoromethyl)phenyl]carbamoylamino]phenyl]sulfonylpyrrolidine-2-carboxamide |
| InChI | InChI=1S/C25H23F3N4O4S/c26-25(27,28)17-8-10-19(11-9-17)30-24(34)31-20-12-14-21(15-13-20)37(35,36)32-16-4-7-22(32)23(33)29-18-5-2-1-3-6-18/h1-3,5-6,8-15,22H,4,7,16H2,(H,29,33)(H2,30,31,34)/t22-/m0/s1 |
| InChIKey | DKFYGSWCJGXEJY-QFIPXVFZSA-N |
| SMILES | C1C[C@H](N(C1)S(=O)(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C(F)(F)F)C(=O)NC4=CC=CC=C4 |
| Reference | [1]. Niu Q, et al. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J Clin Invest. 2019 Jul 22;129(8):3361-3373.<br>[2]. Vansant G, et al. Block-And-Lock Strategies to Cure HIV Infection. Viruses. 2020 Jan 10;12(1). pii: E84.<br>[3]. Brasier AR, et al. Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug Discov Today. 2020 Jan;25(1):126-132. |
